Short News

SLS Stock Today Surges 281%

Published by
Qadir AK

SELLAS Life Sciences (NASDAQ: SLS) shares surged more than 281%, climbing above $28 on trading volume exceeding 200 million shares after the company announced positive results from its pivotal Phase 3 REGAL trial. The trial showed a statistically significant and clinically meaningful improvement in overall survival among patients with acute myeloid leukemia (AML) treated with its cancer vaccine, Galinpepimut-S (GPS). The results could trigger significant short covering, with 57.1 million SLS shares sold short as of October 30, representing 28% of outstanding shares. However, analysts warn that a potential stock offering to fund regulatory filings and commercialization could limit further gains and reduce short-squeeze momentum.

Qadir AK

Qadir Ak is the founder of Coinpedia. He has over a decade of experience writing about technology and has been covering the blockchain and cryptocurrency space since 2010. He has also interviewed a few prominent experts within the cryptocurrency space.

Recent Posts

Goldman Sachs Predicts Gold Price Will Reach $5,600 by 2028

Goldman Sachs forecasts gold prices to reach $4,650 per ounce by the end of 2027…

November 17, 2026

HD Stock Falls 2% Despite Home Depot Earnings Beat as Profit Outlook Tightens

Home Depot (NYSE: HD) shares fell around 2% in pre-market trading despite beating Wall Street…

November 17, 2026

How AI Assistants and PrimeXBT MCP Could Change Crypto Trading Workflows

A crypto trader checking in at any hour may want to know how close their…

November 17, 2026

US Stock Market Today: Mag 7 Stocks Mostly Lower as Health Insurers Decline

Most of the Magnificent 7 stocks traded lower, with Nvidia (NVDA) gaining 1%, Amazon (AMZN)…

November 17, 2026

Grvt wants to make RWA perpetual trading costs easier to plan for. Here’s how

A trade can move in your favour and still leave you with a loss. The…

November 17, 2026

When Does Nvidia Report Earnings

Nvidia will report its third-quarter fiscal 2027 earnings on Tuesday, November 17, 2026, after the…

November 17, 2026